Dr Thomas Joudinaud
CEO Ceres Brain Therapeutics
ICM, Hôpital La Pitié-Salpêtrière
47 Bd de l'Hôpital, 75013 Paris
France

Paris January 21st, 2026

To the ACD Community,

Dear All,

As you know, Ceres Brain Therapeutics is developing a medicine designed to deliver creatine directly to brain neurons. We have demonstrated the potential efficacy of CBT101 in patients with Creatine Transporter Deficiency (CTD) through several animal studies, the results of which have been published in peer-reviewed journals. As a reminder, CBT101 is a nasal spray that must be administered daily in each nostril.

As explained during the last ACD / Xtraordinaire meeting in Paris on September 27th, 2026, we have tested CBT101 in healthy volunteers to demonstrate its safety (Phase 1 study). The study consisted of two parts: a Single Ascending Dose phase, in which groups of volunteers received increasing doses of CBT101, and a Multiple Ascending Dose phase, in which groups received increasing doses administered daily for 14 days. The study was double-blinded, with eight volunteers per group—six receiving CBT101 and two receiving placebo. A total of 48 volunteers participated.

Together with Henri Bénech, Ceres' Chief Operating Officer, and our entire team, I am pleased to inform you that Phase 1 was successful: the nasal administration of CBT101 was well tolerated, and no safety concerns were observed.

During this Phase 1 study, we also monitored the volunteers' brain electrophysiology using quantitative electroencephalograms (qEEG). In volunteers who received CBT101, the qEEG showed significant changes in specific wave bands consistent with improved attentional control. These findings support effective delivery and activity of creatine within neurons, further reinforcing our confidence in CBT101's potential to improve the condition of patients with cerebral creatine deficiency syndromes.

In parallel with the Phase 1 study, we conducted 3-month toxicology studies in rodents and large animals, which were also successful and reported no toxicity. We have continued

developing CBT101, optimizing its manufacturing process to progressively transition toward an industrial-scale product.

We have also initiated a 6-month toxicology study in juvenile animals, as required by regulatory authorities before treating children. Results from this study are expected in Q3 2026.

We are now preparing to evaluate CBT101 in CTD patients (Phase 2), including the production of a new GMP batch and the submission of all required documentation. We anticipate receiving authorization to begin the study at the end of 2026, depending primarily on the results from the juvenile toxicology study and the completion of all product analyses. We must demonstrate to regulatory agencies that the product (1) is safe, (2) has consistent concentration at every dose throughout the study, and (3) remains stable over time.

We expect to conduct the Phase 2 trial in France, testing CBT101 in male and female adults and children. I shall share more information regarding the methodology, timeline, and participating centers once all details will be finalized, hopefully at the next ACD meeting.

As always, the initiation of Phase 2 will depend on the success of our next funding round. We deeply thank our long-standing investors for their continued support and hope to secure the necessary financing.

Our entire team is focused on these upcoming milestones, and I would like to extend my sincere gratitude to the physicians, advisors, and researchers working with us to prepare for the clinical trials.

We are increasingly confident that our medicine will help improve your children's symptoms while remaining easy to administer daily through the CBT101 nasal spray.

At Ceres, we remain fully committed to you and your children, and we look forward to seeing you at the next annual meeting.

Sincerely,

Thomas

Ceres Brain Therapeutics SAS
37 boulevard Berthier 75017 Paris
RCS Paris B 878 506 278